BRIEF — Agomab Announces First Patient Dosed In Global Nov — Era Phase 2B Study Of Ontunisertib In Fibrostenosing Crohn's Disease

Agomab Therapeutics NV: Agomab Announces First Patient Dosed In Global Nov-era Phase 2b Study Of Ontunisertib In Fibrostenosing Crohn's Disease Agomab Therapeutics Nv - Nov-era Phase 2b Study Expected To Enroll About 320 Patients Globally Source text:... Further company coverage: AGMB.O